1. Oura Ring, but aiming for medical-grade accuracy and future non-invasive continuous glucose and blood pressure monitoring.

2. A Fitbit or Apple Watch, but purely focused on advanced, clinical-grade health data from small, dedicated sensors.

3. A future-focused Dexcom for non-invasive continuous glucose monitoring, delivered through a discreet wearable.

• Movano Ring: A wearable device designed to measure vital health parameters like heart rate, sleep, respiration, and activity, with women-centric features.
• Non-invasive Continuous Glucose Monitoring: A technology under development to provide glucose level tracking without invasive procedures.
• Cuffless Blood Pressure Monitoring: A technology under development for continuous blood pressure measurement without a traditional cuff.

Movano Inc. (symbol: MOVE) primarily sells its products directly to individuals.

The company serves the following categories of customers:

1. Health-Conscious Individuals: Consumers who are actively engaged in monitoring their general wellness, including heart rate, sleep patterns, respiration, temperature, and activity levels for overall health and fitness management.
2. Women Seeking Specific Health Insights: Individuals who are interested in features and design tailored for women's health, as the Movano Ring incorporates women-centric aspects. This includes tracking data relevant to menstrual cycles and other female-specific health metrics.
3. Individuals Managing Chronic Conditions or Focusing on Prevention: As the company develops non-invasive continuous glucose monitoring and cuffless blood pressure monitoring, it will target individuals with conditions like diabetes and hypertension, or those at risk, who require ongoing, convenient health monitoring.

John Mastrototaro, PhD - Chief Executive Officer, President & Director

John Mastrototaro has over 30 years of experience in the medical device industry, leading innovation and bringing new products to the market. Before becoming CEO of Movano Health, he was the COO of Orthosensor, Inc., which was acquired by Stryker (NYSE: SYK). He spent the majority of his career with Medtronic and MiniMed, where he was instrumental in initiating and leading a series of firsts in the world of diabetes, including the ambulatory continuous glucose monitoring system, the sensor augmented insulin pump, and early generations of the artificial pancreas.

J. Cogan, CFA - Chief Financial Officer & Secretary

J. Cogan brings 24 years of experience on Wall Street to Movano Health. He previously served as a portfolio manager at Ascend Capital, a multi-billion dollar hedge fund, and as a senior equity research analyst for Banc of America Securities, specializing in the consumer, media, and technology sectors.

Michael Aaron Leabman - Founder, Chief Technology Officer & Director

Michael Leabman is an MIT-educated serial entrepreneur with expertise in RF technology. He has founded four RF-based start-ups and led his last company to an IPO. Leabman holds over 200 patents issued in smart antenna array technology for telecom/power.

Michael Soule - Chief Commercial Officer

Michael Soule has a proven track record of helping small to medium-sized companies grow, including BodyMedia, which was purchased by Jawbone, and Misfit Wearable, which was acquired by Fossil. Most recently, he was the Global Head of Business Development & Partnerships at Bose Health, and prior to that, he was part of the leadership teams at Weight Watchers Health Solutions, Medtronic, and Philips.

Tyla Bucher - Chief Marketing Officer

Tyla Bucher has over two decades of experience building and launching global integrated consumer marketing campaigns for top-tier brands. Before joining Movano, she held various brand strategy and marketing leadership roles at Hasbro, where she oversaw the development of the company's first direct-to-consumer channel. She also served as Vice President Brand Marketing at Twentieth Century Fox, overseeing the execution of strategic business plans across multiple channels for new studio releases.

Key Risks to Movano Inc. (MOVE)

1. Nasdaq Delisting and Compliance Issues: Movano Inc. faces a significant and immediate risk of delisting from the Nasdaq Capital Market due to recurring non-compliance with listing rules. The company has received multiple notices for failing to maintain the minimum $1.00 bid price requirement and for late filings of its quarterly financial reports (Form 10-Q). While Movano plans to appeal these determinations and has submitted compliance plans, there is no assurance that Nasdaq will grant extensions or that the company will successfully regain and maintain compliance, which could severely impact its ability to raise capital and its overall financial condition.
2. Weak Financial Performance and Going Concern Risk: Movano Inc. has consistently incurred significant losses from operations, generated negative cash flows, and holds a substantial accumulated deficit. Its cash and cash equivalents are projected to be insufficient to fund operating requirements beyond 2025, raising substantial doubt about the company's ability to continue as a going concern. The company's stock also faces challenges due to weak financial performance, marked by negative profitability and cash flow issues.
3. Strategic Pivot to AI Infrastructure and Execution Risk: A recent reverse merger with Corvex Inc. has positioned the combined entity as an AI infrastructure platform, representing a significant pivot from Movano's original focus on health wearables. This abrupt change in strategic direction raises serious concerns about strategic coherence and execution risk. Movano's legacy health tech business generates minimal trailing revenue (approximately $500K) and has deeply negative EBITDA of -$15.6M, suggesting a potential destruction of value from its original offerings. The success of this new direction in the highly competitive AI infrastructure market, particularly after a history of financial struggles in its previous domain, presents considerable uncertainty and execution challenges.

The entry of Samsung into the smart ring market with the announced Galaxy Ring poses a clear emerging threat. Samsung is a global technology giant with significant resources for research, development, manufacturing, marketing, and distribution, as well as an established ecosystem of consumer electronics. This directly competes with Movano's primary product, the Movano Ring, which measures similar health metrics and targets the wearable health device market.

For Movano Inc. (symbol: MOVE), the addressable markets for its main products and services are as follows:

• Smart Ring (Evie Ring): The global smart ring market was valued at approximately USD 416.9 million in 2025 and is projected to reach USD 3,772.4 million by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 29.30% during this period. North America held the largest share of this market, accounting for 45.10% in 2025. Another estimate places the global smart rings market size at USD 417.5 million in 2025, projected to reach USD 2,079.3 million by 2033 with a CAGR of 22.5%. Movano's Evie Ring is specifically designed for women, initially targeting women aged 30-75.
• Non-invasive Continuous Glucose Monitoring (CGM): The global continuous glucose monitoring devices market was valued at USD 13.38 billion in 2025 and is projected to reach USD 49.87 billion by 2033, growing at a CAGR of 15.10%. North America is a significant region in this market, holding 63.3% of the global market share in 2025.
• Cuffless Blood Pressure Monitoring: The global cuffless blood pressure monitor market size was valued at USD 585.5 million in 2022 and is expected to grow at a CAGR of 10.9% from 2023 to 2030, reaching USD 1.3 billion by 2030. In 2022, North America dominated this market with a 38.2% share.

Here are 3-5 expected drivers of future revenue growth for Corvex (symbol: MOVE) over the next 2-3 years:

1. Expansion into AI Infrastructure and NVIDIA GPU Deployment: The all-stock merger with Corvex has positioned the combined company, which trades under the symbol MOVE, as an AI infrastructure platform. This strategic pivot includes a long-term NVIDIA H200 GPU deployment, indicating a significant new revenue stream from secure AI inference and high-performance computing, which is expected to capture surging demand in this high-growth sector.
2. Growth in Direct-to-Consumer (D2C) Sales of the Evie Ring: Movano Inc. has reported strong demand for its Evie Ring following initial launches and relaunches. Future revenue growth is anticipated from building inventory, improved capital position and operational efficiencies, and expanded marketing efforts, including the upcoming launch of an Android application, targeting a broader consumer base.
3. FDA Clearance and Business-to-Business (B2B) Healthcare Partnerships for EvieMED Ring: Movano is actively pursuing FDA 510(k) clearance for its EvieMED Ring, which integrates medical-grade pulse oximetry with wellness tracking. Securing this clearance and establishing B2B partnerships with healthcare providers are key initiatives expected to drive revenue from professional healthcare applications.
4. Commercialization of Advanced Health Monitoring Features (Cuffless Blood Pressure and Non-Invasive Glucose Monitoring): The company is advancing clinical trials for non-invasive continuous glucose monitoring and cuffless blood pressure monitoring using its proprietary radiofrequency technology. Successful validation and subsequent commercialization of these highly sought-after features in future wearable devices represent substantial future revenue opportunities.